Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.39 |
| ▸ | LITAF | Q99732 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16901720 | 1.00 | BTK (0.43) | BTKPIK3CAHCAR1TNFLITAF | |
| SCHEMBL16896155 | 0.89 | TNF (0.46) | BTKPIK3CAHCAR1TNFLITAF | |
| SCHEMBL16896156 | 0.89 | TNF (0.46) | BTKPIK3CAHCAR1TNFLITAF | |
| SCHEMBL16896153 | 0.88 | EGFR (0.45) | BTKPIK3CATNFLITAFOPRM1 | |
| SCHEMBL16896151 | 0.88 | EGFR (0.45) | BTKPIK3CATNFLITAFOPRM1 | |
| SCHEMBL29531461 | 0.88 | EGFR (0.45) | BTKPIK3CATNFLITAFOPRM1 | |
| SCHEMBL16767775 | 0.86 | HSD11B1 (0.46) | BTKTNFLITAFOPRM1OGFRL1 | |
| SCHEMBL16767773 | 0.86 | HSD11B1 (0.46) | BTKTNFLITAFOPRM1OGFRL1 | |
| SCHEMBL29531255 | 0.86 | HSD11B1 (0.46) | BTKTNFLITAFOPRM1OGFRL1 | |
| SCHEMBL19046975 | 0.85 | BTK (0.41) | BTKPIK3CAHCAR1TNFLITAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CAPELLA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-10005765-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-9440957-B2 | Compounds and compositions for modulating EGFR Activity | NOVARTIS AG (CH) | 2016-09-13 | — | — | US | disclosed |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787788-B2 | Benzimidazole derivatives, and pharmaceutical compositions and methods of use thereof | CCNI, CYP2C19, PHB1 | BTK 1296/4885PIK3CA 1045/4885HCAR1 3800/4885 |
| US-20170183330-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | BTK 34/4885PIK3CA 96/4885HCAR1 3298/4885 |
| US-20150197505-A1 | Compounds and Compositions for Modulating EGFR Activity | EGFR, ERBB2, ERBB3 | BTK 77/4885PIK3CA 43/4885HCAR1 1970/4885 |
| US-10005765-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | ERBB2, ERBB4, ERBB3 | BTK 34/4885PIK3CA 96/4885HCAR1 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.